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The chloroplastic NADP-malate dehydrogenase is ac-
tivated by thiol/disulfide interchange with reduced thi-
oredoxins. Previous experiments showed that four cys-
teines located in specific N- and carboxyl-terminal
extensions were implicated in this process, leading to a
model where no internal cysteine was involved in acti-
vation. In the present study, the role of the conserved
four internal cysteines was investigated. Surprisingly,
the mutation of cysteine 207 into alanine yielded a pro-
tein with accelerated activation time course, whereas
the mutations of the three other internal cysteines into
alanines yielded proteins with unchanged activation ki-
netics. These results suggested that cysteine 207 might
be linked in a disulfide bridge with one of the four
external cysteines, most probably with one of the two
amino-terminal cysteines whose mutation similarly ac-
celerates the activation rate. To investigate this possi-
bility, mutant malate dehydrogenases (MDHs) where a
single amino-terminal cysteine was mutated in combi-
nation with the mutation of both carboxyl-terminal cys-
teines were produced and purified. The C29S/C365A/
C377A mutant MDH still needed activation by reduced
thioredoxin, while the C24S/C365A/C377A mutant MDH
exhibited a thioredoxin-insensitive spontaneous activ-
ity, leading to the hypothesis that a Cys24-Cys207 disul-
fide bridge might be formed during the activation
process. Indeed, an NADP-MDH where the cysteines
29, 207, 365, and 377 are mutated yielded a permanently
active enzyme very similar to the previously created
permanently active C24S/C29S/C365A/C377A mutant. A
two-step activation model involving a thioredoxin-medi-
ated disulfide isomerization at the amino terminus is
proposed.
NADP-dependent malate dehydrogenase (NADP-MDH)1 (EC
1.1.1.82) catalyzes the reduction of oxaloacetate into malate in
higher plants. In C4 plants, such as sorghum or maize, it is
located in the chloroplasts of mesophyll cells where it partici-
pates in the exportation of reducing equivalents needed for the
photosynthetic fixation of atmospheric CO2 into organic mole-
cules in bundle sheath cell chloroplasts (1). Among all the
malate dehydrogenases studied so far, the NADP-dependent
isoform exhibits a unique property. Whereas MDHs using NAD
are permanently active, the NADP-dependent isoform is totally
inactive in the dark and activated in the light (2). It is now
clearly established that this activation is mediated via the
photosynthetic electron transfer and the ferredoxin/thioredoxin
system and corresponds to the reduction of disulfides present
in the inactive form (3). By thiol derivatization before and after
activation and site-directed mutagenesis, the disulfide bridges
reduced by thioredoxins have been identified (4, 5). To reach
full activity, two disulfide bridges must be reduced: an amino-
terminal one (cysteines 24 and 29) and a carboxyl-terminal one
(cysteines 365 and 377). When these four cysteines are mu-
tated, the mutant protein is permanently active. The two reg-
ulatory disulfide bridges belong to two sequence extensions
characteristic of the NADP-dependent isoform and absent from
the NAD-dependent isoforms (6). It has been proposed that the
carboxyl-terminal extension shielded the access to the active
site in the oxidized form and moved upon reduction (7),
whereas the reduction of the amino-terminal bridge triggered a
slow conformational change shaping the active site in a high
activity conformation (5).
The four regulatory cysteines have no catalytic role since
their replacement by alanines does not impair the catalytic
activity. Nevertheless, it has been shown that the NADP-MDH
activity was sensitive to thiol reagents, such as iodoacetate or
iodoacetamide. Moreover, the permanently active C24A/C29A/
C365A/C377A mutant protein is sensitive to diamide, a reagent
known to reoxidize vicinal thiols into disulfides (5). This obser-
vation suggested that an internal cysteine might be important
for catalytic activity and also raised the question of the possible
existence of an internal disulfide bridge. The NADP-MDH con-
tains eight cysteines, at strictly conserved positions for all the
NADP-isoforms; these conserved cysteines are not found in the
NAD-dependent isoforms (6). Four of those cysteines, belonging
to sequence extensions, have been shown to play a role in the
activation process and are not involved in catalytic activity.
Concerning the four internal cysteines (cysteines 175, 182, 207,
and 328), Cys175, located at the active site, has been studied
earlier and shown to have no catalytic function (8). In the
present study, we examined the possible role of the three other
internal cysteines in the activity of the enzyme. Quite unex-
pectedly, one of them, i.e. Cys207, appeared to have a role in the
reductive activation of the enzyme.
EXPERIMENTAL PROCEDURES
Materials—Restriction endonucleases, DNA modification enzymes,
T4 DNA ligase, and T4 DNA polymerase were from Appligene. DEAE-
Sephacel and Matrex Red A chromatographic supports were respec-
tively from Pharmacia and Grace-Amicon. Chemicals (from Sigma,
Boehringer, or Prolabo) were of analytical grade. Oligonucleotides were
purchased from Eurogentec. Radiolabels were from Amersham Corp.
Escherichia coli strain XL1 blue (CLONTECH) was used to produce
high yields of plasmids and M13 single-stranded DNA. All the other
strains and vectors were the same as described in Ref. 9. E. coli strain
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RZ1032 and M13mp19 phage (Pharmacia Biotech Inc.) were used to
produce deoxyuridine-substituted M13 single-stranded DNA for site-
directed mutagenesis, pUC9 was used when needed for cloning strat-
egy, and E. coli strain BL21 (DE3) (10) was used for the production of
mutated NADP-MDHs encoded by recombinant pET-8c vectors. Bacte-
ria were grown at 37 °C on Luria broth medium; ampicillin at 50 mg/ml
was added when the bacteria carried plasmids conferring drug
resistance.
Preparation of Mutated mdh cDNAs—The cDNAs encoding the
NADP-MDHs bearing the single mutations C207A, C207S, C182A, and
C328A were obtained by site-directed mutagenesis using the method of
Kunkel (11). The single-stranded M13 template used was M13mdh, a
vector in which the wild-type NADP-MDH cDNA is cloned (9). The
mutagenic oligonucleotides are presented in Table I. A screening of the
mutants was performed by sequencing single-stranded M13 DNA ob-
tained from a few plaque isolates. The cDNA coding for the NADP-MDH
with the double mutation C175A/C207A was obtained using the same
method and the same template except that for the annealing reaction a
mixture of both mutagenic oligonucleotides was used (see Table I).
The cloning strategies used to combine the mutations are summa-
rized in Fig. 1. The cDNAs bearing the mutations C24S/C365A/C377A,
C29S/C365A/C377A, and C207A/C365A/C377A were obtained by ex-
changing the NcoI-NheI fragment of the C365A/C377A mdh cDNA
cloned in pUC9 for the corresponding fragment of, respectively, C24S
mdh cDNA, C29S mdh cDNA, and C207A mdh cDNA. To obtain the
cDNA with the double mutation C207A/C328A, the NheI-BamHI frag-
ment of the C207A/C365A/C377A mdh cDNA cloned in pUC9 was
exchanged for the corresponding fragment of the C328A mdh cDNA.
Because the NheI-BamHI encompasses cysteines 328, 365, and 377,
this cloning strategy yields a cDNA containing only the mutations
C207A and C328A. The C29S/C207A/C365A/C377A cDNA was obtained
by exchanging the ApaI-ApaI fragment of the C207A/C365A/C377A
mdh cDNA cloned in pUC9 for the corresponding fragment of the
C29S/C365A/C377A mdh cDNA. The NcoI-BamHI fragments of all the
mutated MDH cDNAs were transferred to a pET vector for production
of the modified proteins.
DNA Sequencing—The DNA sequencing was done using the dideoxy
chain termination method (12) (T7 sequencing kit, Pharmacia). For
every mutated cDNA, the sequence of the whole NcoI/BamHI fragment
in the expression vector was checked prior to recombinant protein
production.
Production and Purification of Recombinant NADP-MDHs—The mu-
tated NADP-MDHs were produced using the pET/BL21 production
system. The experimental procedures for the production in E. coli and
purification of the recombinant proteins were essentially as described
in Ref. 9. The main steps consisted of ammonium sulfate fractionation,
ion-exchange chromatography on DEAE-Sephacel, and affinity chroma-
tography on Matrex Red A. When needed, a hydrophobic interaction
step on TSK Phenyl 5PW was added. The column was equilibrated with
1.8 M ammonium sulfate in 0.1 M potassium phosphate buffer, pH 7.2.
The enzyme was eluted with a linear decreasing gradient of ammonium
sulfate (1.8–0 M) in the same buffer. The NADP-MDH was then dia-
lyzed against 20 mM potassium phosphate buffer, pH 7.2, 1 mM EDTA
and concentrated.
Polyacrylamide Gel Electrophoresis—Proteins were separated by
vertical SDS-PAGE following the method of Schägger and von Jagow
(13). They were visualized by Coomassie Brilliant Blue staining.
Protein Sequencing—The amino-terminal sequence of the purified
proteins was verified with an Applied Biosystems model 476A auto-
mated sequencer equipped with an on-line phenylthiohydantoin-deriv-
ative analyzer.
Molecular Mass Determination by Size Exclusion Chromatography—
Gel filtration experiments were performed using a TSK 3000 SW col-
umn (300 3 7.5 mm). After loading the protein, elution was achieved
with a 30 mM Tris-HCl, pH 7.9 buffer, containing 0.15 M NaCl. Polypep-
tides with known molecular masses were used as standards.
Activation and Enzyme Activity Assays—The enzymes were activated
at 25 °C, in 100 mM Tris-HCl buffer, pH 7.9, by 20 mM E. coli thiore-
doxin, reduced either chemically with 10 mM DTT or photosynthetically
in a reconstituted light activation system (14). Recombinant E. coli
thioredoxin was purified as in Ref. 15. NADP-MDH activity was meas-
ured on aliquots, at 30 °C, by following the decrease in absorbance at
340 nm, in a standard assay mixture (1 ml) containing 100 mM Tris-
HCl, pH 7.9, 780 mM oxaloacetate, and 140 mM NADPH. The Km values
for NADPH and oxaloacetate were determined on preactivated en-
zymes, unless otherwise indicated, by varying the concentrations of
each substrate, the other being kept constant. S1⁄2 for thioredoxin were
determined by measuring the initial rates of NADP-MDH activation in
the presence of different concentrations of thioredoxin.
DEPC Treatment—The sensitivity of the C207A and C207A/C365A/
C377A mutant MDHs to inhibition by DEPC was tested by adding the
reagent at a 1 mM concentration either before or after activation of the
enzymes in the same conditions as described in Refs. 7 and 16. Sub-
strate protection experiments were performed on the C207A/C365A/
C377A mutant by adding 1 mM NADPH before the DEPC treatment.
After the treatment, the enzyme was extensively dialyzed and submit-
ted to activation by DTT-reduced thioredoxin.
RESULTS
Production and Study of the NADP-MDHs Mutated on Inter-
nal Cysteines—As mentioned in the introduction, the NADP-
MDH mutated on Cys175 had been studied earlier (7). To get a
complete picture of the roles of cysteines in NADP-MDH, the
three other internal cysteines, e.g. Cys182, Cys207, and Cys328,
were individually mutated into alanines. After production in E.
coli and purification to homogeneity, the three mutant proteins
were found to be still active after activation by reduced thiore-
doxins. It thus appeared clearly that none of the internal cys-
teines was necessary for the catalytic process. No spontaneous
activity could be measured prior to activation. Activation ki-
netics were followed by measuring NADP-MDH activity as a
function of time after addition of thioredoxins reduced either
chemically by DTT (Fig. 2) or photosynthetically in a reconsti-
tuted light activation system (data not shown). The activation
time courses of the C182A and C328A mutant proteins, as well
as the half-saturation concentrations for thioredoxins (S1⁄2),
were similar to those of the wild-type enzyme and of the C175A
mutant studied previously (7). In contrast, the C207A mutant
protein exhibited an accelerated activation time course and a 2
to 3 times lower S1⁄2 for thioredoxin (Table II).
The kinetic parameters of the mutant proteins were also
determined after full activation (see Table II). No significant
differences for the Km OAA could be detected between the
proteins mutated on cysteine 182, 207, or 328 and the WT
enzyme. The Km NADPH of the C328A NADP-MDH was close
to that of the WT enzyme. The Km NADPH of the C182A and
C207A mutants was about 4 times higher than that of the WT
enzyme. When kcat values of the different mutants were com-
pared, it appeared that the replacement of cysteine 182 or 207
did not impair but increased the catalytic activity (respectively
about 5- and 2-fold), whereas the replacement of Cys328 by
alanine resulted in a decrease of the catalytic activity (by about
TABLE I
Oligonucleotides used to introduce site-directed mutations
into the mdh cDNA
The bases underlined were introduced to replace the codons (written
in bold) initially encoding a cysteine with codons coding for a serine or
an alanine.
Introduced
modification Mutagenic primer sequence
C175A pGGAAATCCCGCTAACACTA
C182A pGCGTTAATTGCCTTGAAAAATGC
C207A pGAGCAAAGCCCAGCTAG
C207S pGAGCAAAGAGCCAGCTAG
C328A pCAGCATGCCAGCCATCGAA
FIG. 1. Representation of the NcoI-BamHI fragment of the
cDNA of Sorghum vulgare NADP-MDH. The restriction sites of
ApaI and NheI are represented. The relative positions of codons encod-
ing some cysteines are visualized; the numbers refer to the cysteines
encoded.
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2 times). Thus the presence of a cysteine at position 328 seemed
to be favorable for the catalytic activity even though it was not
directly implicated in the catalytic process. The higher Km
NADPH of the C182A NADP-MDH suggested a possible role of
Cys182 in the coenzyme binding, in accordance with its pre-
dicted position, close to the nicotinamide ring of the cofactor (5).
The overall effects of these individual mutations on the cata-
lytic efficiencies of the mutated proteins (kcat/Km) were rather
limited, increased kcat being compensated by increased Km for
NADPH. In contrast, the acceleration of the activation rate
upon replacement of Cys207 by an alanine was rather unex-
pected and suggested that this cysteine could be involved in the
activation process.
To strengthen this hypothesis, this residue was also replaced
by a serine. The C207S mutant protein exhibited the same
kinetic parameters as the C207A mutant protein, that is a Km
OAA close to that of the wild-type enzyme, and a Km NADPH
about 3 times higher (Table II). Concerning the activation
process, the C207S mutant protein exhibited an accelerated
activation time course and a lower S1⁄2 for thioredoxin, i.e.
characteristics similar to those of the C207A mutant (Table II
and Fig. 2) and to those obtained previously for the amino-
terminal mutants mutated on either or both of the most amino-
terminal cysteines (9).
Based upon these experiments, it could be concluded that
cysteines 182, 207, and 328, like the previously studied Cys175,
have no direct catalytic role in NADPH-MDH, but that Cys207
seemed to be implicated in the activation process.
Involvement of Cysteine 207 in the Activation by Thioredox-
ins—In previous studies (5, 7), we have shown that the removal
of the carboxyl-terminal disulfide of NADP-MDH by mutation
of cysteines 365 and/or 377 opened the access to the active site
but did not accelerate the slow activation rate of the enzyme
which was linked to the presence of the amino-terminal disul-
fide. In contrast, mutation of amino-terminal cysteines (Cys24
and/or Cys29) accelerated the activation rate (9) and loosened
the interaction between subunits (17) but did not give access to
the active site. The kinetic effects of mutation of Cys207 into
alanine or serine described above strongly suggested that this
residue was involved in the activation process but did not
identify the step in which this cysteine was implicated.
The role of the carboxyl-terminal bridge had been suggested
first by the existence of a slight spontaneous activity in the
mutants where the carboxyl-terminal disulfide had been re-
moved. Supporting evidence for this role came from experi-
ments using DEPC, a histidine-derivatizing reagent, which has
been shown to constitute a good probe of the accessibility of the
active site (16): it inhibits the enzyme activity only when the
carboxyl-terminal disulfide bridge is open by reduction or sup-
pressed by site-directed mutagenesis. To investigate a possible
role of Cys207 in the accessibility of the active site, the effect of
DEPC was tested before and after the activation of the C207A
mutant MDH. The activated mutant was inhibited by DEPC to
the same extent as the activated WT enzyme (data not shown),
but no inhibition occurred when the reagent was applied prior
to activation, i.e. the mutant enzyme could be fully activated by
reduced thioredoxin after removal of DEPC (Fig. 3). In con-
trast, when the C207A mutation was combined with the double
mutation C365A/C377A which eliminates the carboxyl-termi-
nal disulfide, the unactivated enzyme was inhibited by DEPC
and could not be activated further (Fig. 3). As in the case of the
double carboxyl-terminal mutant, NADPH provided a protec-
tion against inhibition (data not shown). Clearly, the mutation
of Cys207 alone did not give access to the active site. Interest-
ingly, the combined triple mutant exhibited a higher sponta-
neous activity than the corresponding double carboxyl-termi-
nal mutant: about 20% of the activity of the activated enzyme
(Fig. 3) versus about 5% for the latter (5). Thus, a Km for
NADPH and a Km for oxaloacetate could be measured for the
non-activated triple mutant enzyme (Table III). The Km for
oxaloacetate of this enzyme prior to activation was found to be
220 mM, a value falling between the Km of the fully activated
C207A/C365A/C377A triple mutant or WT enzymes (approxi-
mately 38 mM, Tables II and III) and the Km of the non-acti-
vated C365A/C377A NADP-MDH (1100 mM, Ref. 5). In other
words, in the enzyme mutated on Cys207, the conformation of
FIG. 2. Activation kinetics of NADP-MDH bearing single mu-
tations on internal cysteines. The wild-type and mutant MDHs were
activated by 20 mM thioredoxins reduced by 10 mM DTT. The results are
expressed as percentage of maximum activity. The activation rates of
the proteins mutated on Cys207 are similar to those of the previously
studied mutants on Cys24 and Cys29 (Ref. 9).
TABLE II
Kinetic parameters of the wild-type and mutant NADP-MDHs
Kinetic parameters were determined at 30 °C, pH 7.9, with the purified preparations of the wild-type and mutant NADP-MDHs fully
preactivated by 20 mM thioredoxin and 10 mM DTT. The Km for oxaloacetate was determined at a saturating concentration of NADPH (210 mM for
C207A and C207S; 140 mM for wild-type, C182A, and C328A) with concentrations of OAA ranging from 7.5 to 1500 mM. The Km for NADPH was
determined at a saturating concentration of oxaloacetate (780 mM) with concentrations of NADPH ranging from 1.4 to 210 mM. The S1/2 thioredoxin
were determined by varying the thioredoxin concentration in the preincubation medium from 0.5 to 40 mM and measuring the activation rate of
the enzyme in the presence of saturating substrate concentrations.
kcat
Km kcat/Km
S1/2 thioredoxin
a
NADPH Oxaloacetate NADPH Oxaloacetate
s21 mM mM21 z s21 mM
Wild-type 630 40 (6 8) 37 (6 5) 16 17 10.5 (6 0.5)
C182A 3000 111 (6 13) 65 (6 7) 27 46 12.0 (6 0.5)
C207A 1532 123 (6 34) 72 (6 33) 14 21 3.9 (6 0.2)
C207S 1073 123 (6 34) 123 (6 60) 9 9 4.2 (6 0.1)
C328A 318 20 (6 3) 26 (6 8) 16 33 13.8 (6 0.4)
a The S1/2 thioredoxin for the C24S, C29S, and C24S/C29S mutants was 3 mM (Ref. 9).
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the oxaloacetate binding site was intermediary between the
low affinity conformation of the unactivated wild-type enzyme
and the high affinity conformation of the fully activated wild-
type enzyme. This was an additional indication that Cys207 is
implicated in the activation process. More specifically, this
result suggested that this cysteine is involved in the conforma-
tional change of the active site proposed to occur upon the
reduction of the amino-terminal bridge. Another feature sug-
gesting that the Cys207 mutation exhibited characteristics sim-
ilar to those of the amino-terminal Cys mutations rather than
the carboxyl-terminal Cys mutations is the sensitivity of the
activation of this mutant to inhibition by NADP (data not
shown), which is a a well known property of the WT enzyme
and amino-terminal mutants and which is suppressed by mu-
tation of the carboxyl-terminal cysteines (5). The question can
be raised of whether, as is the case for the amino-terminal
cysteine mutations, the mutation of Cys207 loosened the inter-
action between subunits. To answer this question, size exclu-
sion chromatography experiments were run on the unactivated
C207A mutant under varying ionic strength conditions. How-
ever, the oxidized protein behaved much like the WT protein,
i.e. could not be dissociated into monomers under these condi-
tions (data not shown).
Function of Cysteine 207 in the Activation by Thioredox-
ins—In a protein, the role of a cysteine residue can be related
either to its hydrogen bonding capacity or to its hydrophobicity
or to its ability to form a disulfide bridge. As the hydrophobic
properties of cysteine are shared by alanine, and its hydrogen-
bonding properties are similar to those of a serine, the identical
results obtained with the mutations C207A and C207S are
strongly in favor of the hypothesis that Cys207 reacts with
another cysteine to form a disulfide bridge. In this case, a
partner cysteine should be found, the mutation of which should
yield the same modifications in the activation kinetics as the
mutation of Cys207. None of the mutations of the other internal
cysteines (cysteines 175, 182, and 328) altered the activation
kinetics. Furthermore, combined mutations of each of these
cysteines with Cys207 yielded proteins showing properties iden-
tical to those of the single Cys207 mutant (data not shown).
Thus the formation of a disulfide bridge between any of these
cysteines and Cys207 can be ruled out. Among the four regula-
tory cysteines located in extensions, single or double mutation
of Cys365 and Cys377 did not yield accelerated activation time
courses (5). Furthermore, as described above, the single muta-
tion of Cys207 did not open the access to the active site and did
not relieve the inhibition of activation by NADP. Thus it is
highly unlikely that the partner cysteine of Cys207 would be one
of the carboxyl-terminal cysteines. In contrast, the effects of
mutation of Cys207 shared characteristics common with the
mutation of the amino-terminal cysteines 24 and/or 29: acceler-
ated activation time course and decreased S1⁄2 for thioredoxin (9).
This suggested that the partner cysteine of Cys207 in a disulfide
bridge might be one of the two amino-terminal cysteines.
From previous studies, it had been concluded that the acti-
vation of NADP-MDH required the reduction of only two di-
sulfides per monomer (5). This conclusion was based on the
observation that both single or double amino-terminal muta-
tions similarly accelerated the activation kinetics and that the
combined mutation of the two most amino-terminal cysteines
with either or both of the two most carboxyl-terminal cysteines
yielded permanently active proteins. However no attempt to
differentiate between possible different roles of Cys24 and
Cys29 in proteins where the carboxyl-terminal bridge had been
removed by mutation had been made. To fill this gap, proteins
in which a single mutation of one of the two amino-terminal
cysteines was combined with the mutation of the two carboxyl-
terminal cysteines were produced. The biochemical properties
of the C24S/C365A/C377A NADP-MDH resembled those of the
previously created C24S/C29S/C365A/C377A quadruple mu-
tant. It was permanently active, and its activity could be fol-
lowed throughout the purification procedure without preacti-
FIG. 3. Test of the accessibility of the active site of the C207A
mutant NADP-MDH either singly or combined with the muta-
tion of the two most carboxyl-terminal cysteines. The unactivated
enzymes were treated with 1 mM DEPC for 5 min. Then the reagent was
eliminated by dialysis, the activation medium (DTT 1 thioredoxin) was
added, and the activity was measured on aliquots as a function of time.
C207A/2C, C207A/C365A/C377A.
TABLE III
Kinetic parameters of mutant NADP-MDHs
The Km for substrates of the oxidized proteins were determined either by varying NADPH from 2.8 to 280 mM at saturating concentrations (3.75
mM) of oxaloacetate or oxaloacetate from 7.5 mM to 7.5 mM at saturating concentration (140 mM) of NADPH. The Km for substrates of the reduced
proteins were determined on proteins fully activated by preincubation by 20 mM thioredoxin and 10 mM DTT. The NADPH ranged from 2.8 to 280
mM at a saturating concentration (780 mM) of oxaloacetate, and oxaloacetate ranged from 7.5 mM to 1.5 mM at a saturating concentration (140 mM)
of NADPH. The S1/2 thioredoxin were determined by varying the thioredoxin concentration in the preincubation medium from 0.5 to 40 mM and
measuring the activation rate of the enzyme in the presence of saturating substrate concentrations.
Protein
Km
S1/2 thioredoxin
a
OAA NADPH
mM mM mM
C24S/C365A/C377A 57 (6 15) 128 (6 39)
C29S/C207A/C365A/C377A 79 (6 5) 100 (6 32)
Oxidizedb Reduced Oxidized Reduced
C207A/C365A/C377A 220 (6 72) 38 (6 5) 33 (6 7) 52 (6 7) 4.0 (6 0.5)
C29S/C365A/C377A 477 (6 66) 82 (6 22) 97 (6 6) 163 (6 52) 3.8 (6 0.2)
a The S1/2 thioredoxin of the C365A/C377A mutant was 13 mM (Ref. 5).
b The Km OAA of the oxidized C365A/C377A mutant was 1100 mM (Ref. 5).
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vation (data not shown). However, as it was also rather
unstable and susceptible to oxidation, maximal activity of the
pure protein could be obtained only if 1 mM DTT were included
in the reaction medium (Fig. 4). In contrast, the C29S/C365A/
C377A NADP-MDH still required activation by reduced thiore-
doxin to reach full activity (Fig. 4). Its activation rate was very
similar to the activation rate of the C207A/C365A/C377A mu-
tant, but its spontaneous activity was very similar to that of the
C365A/C377A NADP-MDH, i.e. approximately 5% of the activ-
ity of the fully activated protein. The Km OAA of the unacti-
vated enzyme (477 mM) was higher than that of the fully acti-
vated enzyme (66 mM, Table III) but somewhat lower than that
of the non-activated C365A/C377A NADP-MDH (1100 mM, Ref.
5). Clearly, this mutant shared some similarities with the
C207A/C365A/C377A mutant but also exhibited some notable
differences. In particular, despite the fact that the thioredoxin-
dependent activation of both mutants proceeded at similar
rates, the C207A/C365A/C377A mutant could be fully activated
either by DTT or by mercaptoethanol alone, although much
more slowly, whereas the C29S/C365A/C377A mutant was
strictly dependent on reduced thioredoxin for activation (Fig.
4). The thioredoxin dependence of the activation can be unam-
biguously established by using a reconstituted light activation
system in which thioredoxins are reduced by the photosyn-
thetic electron transfer. In this system both C207A/C365A/
C377A and C29S/C365A/C377A triple mutants were activated
at higher rates than was the WT protein, without the typical
lag in activation of the latter (Fig. 5). In contrast, when the
C24S/C365A/C377A mutant was assayed in this system after
having been inactivated by dilution, its activity could not be
restored unless DTT was added either to the activation me-
dium or to the reaction cuvette (Fig. 5).
Summarizing the results obtained with the three combined
triple mutations, it can be concluded that whereas in the C24S/
C365A/C377A mutant there was no thioredoxin-reducible di-
sulfide bridge left, a thioredoxin-reducible disulfide was still
present in both the C29S/C365A/C377A and the C207A/C365A/
C377A mutants. This observation suggested that Cys24 could
form a disulfide bridge with Cys29, as shown previously, or
alternately with Cys207. If this interpretation is valid, a quad-
ruple mutant combining the mutation of Cys29 and Cys207
should yield a permanently active protein. This was indeed the
case (Fig. 5). The C29S/C207A/C365A/C377A NADP-MDH was
fully active, and its activity could not be enhanced by reduced
thioredoxin. Its kinetic properties were very similar in all re-
spects to those of the previously created C24S/C29S/C365A/
C377A quadruple mutant (5) and, more generally, to those of
the activated WT enzyme (Table III).
DISCUSSION
The present work where the roles of Cys182, Cys207, and
Cys328 of NADP-MDH were examined allows us to draw a
general picture of the roles of the eight strictly conserved cys-
teines of NADP-MDH. It rules out the direct involvement of
any cysteine in the catalytic process. It confirms the previously
proposed hypothesis that the four cysteines belonging to se-
quence extensions participate in the activation of the enzyme.
Among the internal cysteines, Cys182 and Cys328, as well as the
previously studied Cys175 (8) clearly have no role in activation.
Their substitution by site-directed mutagenesis did not modify
the activation kinetics. In contrast, mutation of Cys207 into
either Ala or Ser yielded mutants with accelerated activation
rates. This suggested that the role of Cys207 was neither related
to its hydrophobicity nor to its hydrogen-bonding capacity but
specifically to its ability to form disulfide bridges. This conclu-
sion was rather unexpected, as none of the three other internal
cysteines induced similar modifications upon mutation, and
hence none of them could be a partner of Cys207. On the other
hand, the four external cysteines had already been shown to be
paired: Cys24 with Cys29 and Cys365 with Cys377. A closer
analysis of the properties of the Cys207 single mutant proteins
showed that they shared a number of characteristics with the
proteins mutated on the Cys of the amino-terminal extension.
Their activation rates were accelerated, and their half-satura-
tion concentrations for thioredoxin were lowered to the same
extent (9). In contrast, they did not show any of the character-
istics of the enzymes mutated at the two most carboxyl-termi-
nal cysteines, i.e. slight spontaneous activity, slow activation
kinetics, accessibility of the active site histidine to DEPC in the
FIG. 4. Activation of the triple mutant MDHs by reduced thi-
oredoxins or by chemical reductants. C24/2C, C24S/C365A/
C377A; C29/2C, C29S/C365A/C377A; C207/2C, C207A/C365A/C377A.
The C207/2C mutant was treated either with 20 mM thioredoxin 1 10
mM DTT or with 10 mM DTT or with 100 mM b-mercaptoethanol. The
C29/2C mutant was treated either with 20 mM thioredoxins 110 mM
DTT or with 10 mM DTT. The C24/2C mutant was treated with 1 mM
DTT. After addition of the reductant, the activity was assayed on
aliquots as a function of time. The results are expressed in percent of
maximum activity. The activity was assayed with 780 mM OAA (a
concentration which is not saturating for the unactivated triple
mutants).
FIG. 5. Light-dependent activation of combined Cys mutant
NADP-MDHs in a complete reconstituted light activation sys-
tem. The activity was assayed on aliquots as a function of time after
turning on the light. Single or double amino-terminal mutations were
introduced into a mutant MDH where the two most carboxyl-terminal
cysteines had been substituted by site-directed mutagenesis. C24/2C,
C24S/C365A/C377A; C29/2C, C29S/C365A/C377A; C207/2C, C207A/
C365A/C377A; C29/C207/2C, C29S/C207A/C365A/C377A. The results
are expressed as percentage of maximum activity.
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unactivated form, and lack of inhibition of activation by NADP
(5). In an attempt to identify unequivocally, among the three
cysteines yielding similar functional consequences upon muta-
tion, the cysteine pair implicated in activation, cumulated mu-
tations of each of these cysteines were performed on enzymes
where the carboxyl-terminal bridge was removed by mutagen-
esis. The functional consequences of these mutations are sum-
marized in Fig. 6. When a permanently active, thioredoxin-
insensitive enzyme was obtained, it could be concluded that no
reducible disulfide remained. If the mutant enzyme was still
activable by reduced thioredoxin, the position of the remaining
disulfide could be identified. From Fig. 6 it is clear that a
thioredoxin-reducible disulfide can be formed between Cys24
and Cys29 (the previously identified amino-terminal regulatory
disulfide) and also between Cys24 and Cys207. The question of
the physiological relevance of these alternate disulfides is of
obvious importance. The mere fact that both of them were
much more efficiently reduced by thioredoxin than by DTT
suggests that both belong to a physiological process. The pres-
ence of the Cys24–Cys29 disulfide was first established on the
basis of chemical derivatization and amino acid sequencing. In
the unactivated enzyme, both amino-terminal cysteines were
unavailable to derivatization and hence appeared as gaps in
amino acid sequencing. Both became available (and visible in
the primary sequence) after full activation of the enzyme (4).
Based on this evidence, the amino-terminal disulfide initially
present in the oxidized enzyme can be identified as the Cys24–
Cys29 disulfide. The mutant protein where only this disulfide
remained was activated much more efficiently by reduced thi-
oredoxin than by DTT alone. It could be fully activated by DTT,
although much more slowly. The mutant protein where only
the Cys24–Cys207 bridge remained was also activated very ef-
ficiently by reduced thioredoxin but could not be activated by
DTT alone under standard low ionic strength conditions. Sim-
ilarly, under the same conditions, the WT protein could not be
activated by DTT alone, the only difference between the mu-
tant and WT proteins being the slower activation rate of the
WT enzyme. These observations strongly suggest that the
Cys24–Cys207 bridge is a thioredoxin-reducible physiologically
important disulfide bridge formed during the activation proc-
ess and that the faster activation of the mutant protein con-
taining this single disulfide results from the fact that one
activation step had been suppressed by mutation, namely, the
reduction of the amino-terminal Cys24–Cys29 disulfide. The
slow activation rate linked to the reduction of the amino-ter-
minal disulfide bridge has been previously ascribed to a slow
conformational change following reduction, the disulfide reduc-
tion per se being fast. The present mutagenesis experiments
suggest that this conformational change is linked to the isomer-
ization of amino-terminal disulfides followed by a second re-
duction step. It has been shown previously that the elimination
of the amino-terminal disulfide by site-directed mutagenesis
(9) or by proteolysis (18, 19) weakened the interaction between
subunits. No such effect was observed upon mutation of Cys207.
On the other hand, mutation of Cys207 or, to a lesser extent,
Cys29 combined with the mutation of the two carboxyl-terminal
cysteines led to a decrease in the Km OAA of the unactivated
proteins (Table III), suggesting that these residues (and espe-
cially Cys207) are involved in the conformational change of the
active site toward a higher efficiency.
In an attempt to visualize the succession of events following
the reduction of the Cys24–Cys29 disulfide bridge, we propose
that this reduction would be followed by the formation and
further reduction of a Cys24–Cys207 disulfide bridge, the forma-
tion of this second disulfide being favored by the loosening of
the interaction between subunits. This proposal is supported by
structural data. The core part of NADP-MDH has been mod-
eled using the coordinates of the crystal structure of NAD-
MDH (5, 20). In the model, Cys207 appears to be located at the
subunit interface, in a half-buried position. A change in the
interaction between subunits can bring it into a more exposed
position. In this regard, it should be mentioned that Cys207 was
one of the cysteines Reng et al. (21) proposed to be implicated in
the activation process of pea NADP-MDH and that an amino-
terminally truncated pea MDH is able to form mixed disulfides
with glutathione (22).
FIG. 6. Summary of the results of combined cysteine mutations
of NADP-MDH. The residues replacing the cysteines are written in
bold; the putative disulfide bridges are visualized by a link between
cysteines.
FIG. 7. Model of the activation of dimeric NADP-MDH by thioredoxins. The carboxyl-terminal extensions are on the outside of each
monomer, close to the opening of the active site. The amino-terminal extensions are at the dimer contact area. The coenzyme binding site is figured
by a diamond and oxaloacetate by a triangle. In the oxidized state, Cys207 which is situated in the vicinity of dimer contact area is half-buried. The
carboxyl-terminal extensions shield the active site in the unactivated enzyme and move upon reduction. The reduction of the amino-terminal
extensions loosens the interaction between monomers, thus triggering a slow conformational change of the active site and making Cys207 accessible.
A Cys207–Cys24 bridge is then formed. After reduction of this bridge, the conformational change of the active site is completed, yielding an active
site with high affinity for OAA.
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The updated functional model we propose for NADP-MDH
activation (Fig. 7) accomodates all the experimental data gath-
ered from site-directed mutagenesis experiments. It is also
consistent with the existence of the “preregulatory” disulfide
bridge proposed by Hatch and Agostino (23). These authors
observed that a pretreatment of NADP-MDH with mercapto-
ethanol did not activate the enzyme but accelerated its further
activation by reduced thioredoxin. Such a result can be ex-
pected if mercaptoethanol reduced the Cys24–Cys29 bridge but
was unable to reduce either the Cys24–Cys207 bridge formed
subsequently (Fig. 5) or the Cys365–Cys377 bridge (5, 9).
In the light of the present results, the reductive activation of
NADP-MDH by thioredoxin can be viewed as a protein unfold-
ing pathway, the activation resulting not only from reduction of
disulfides but also from their transient isomerization leading to
a conformational change of the active site. Until now, isomer-
ization of disulfides was shown to be an obligate step of the
protein folding pathway (24), but recently it has been demon-
strated that isomerization could also occur upon an unfolding
triggered by disulfide reduction (25). Correct protein folding is
considered to be catalyzed by protein-disulfide isomerase (26),
which is a strong oxidant. However, thioredoxin was also
shown to possess a disulfide isomerase activity (27). The pres-
ent work suggests that thioredoxin could also be involved in the
isomerization of disulfides in conjunction with its disulfide
reducing function. The case of NADP-MDH is the best docu-
mented among the light-activated chloroplastic enzymes in this
respect. However, it is not the only known example. Recent
mutagenesis experiments on the thioredoxin-regulated chloro-
plastic fructose-1,6-bisphosphatase showed that three cys-
teines were involved in the reductive activation of the enzyme
(28). Thus the light regulation of some chloroplastic enzymes
could be viewed as a general regulation process in which thi-
oredoxin, in addition to its disulfide reducing activity, fulfills a
disulfide isomerase function, thus ensuring a correct folding/
unfolding of the light-regulated enzymes.
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15. de Lamotte-Guéry, F., Miginiac-Maslow, M., Decottignies, P., Stein, M.,
Minard, P., and Jacquot, J-P. (1991) Eur. J. Biochem. 196, 287–294
16. Lemaire, M., Schmitter, J-M., Issakidis, E., Miginiac-Maslow, M., Gadal, P.,
and Decottignies, P. (1994) J. Biol. Chem. 269, 27291–27296
17. Miginiac-Maslow, M., Issakidis, E., Lemaire, M., Ruelland, E., Jacquot, J.-P.,
and Decottignies, P. (1997) Austr. J. Plant Physiol. 24, in press
18. Kampfenkel, K. (1993) Biochim. Biophys. Acta 1156, 71–77
19. Ocheretina, O., Harnecker, J., Rother, T., Schmid, R., and Scheibe, R. (1993)
Biochim. Biophys. Acta 1163, 10–16
20. Jackson, R. M., Sessions, RB., and Holbrook, J. J. (1992) J. Comput. Aided Mol.
Des. 6, 1–18
21. Reng, W., Riessland, R., Scheibe, R., and Jaenicke, R.(1993) Eur. J. Biochem.
217, 189–197
22. Ocheretina, O., and Scheibe, R. (1994) FEBS Lett. 355, 254–258
23. Hatch, M. D., and Agostino, A. (1992) Plant Physiol. 100, 360–366
24. Goldenberg, D. P. (1991) Trends Biochem. Sci. 17, 257–261
25. Chang, J-Y. (1997) J. Biol. Chem. 272, 69–75
26. Hennecke, J., Spleiss, C., and Glockshuber, R. (1977) J. Biol. Chem. 272,
189–195
27. Hawkins, H. C., Blackburn, C., and Freedman, R. B. (1991) Biochem. J. 275,
349–353
28. Jacquot, J-P., Lopez-Jaramillo, J., Miginiac-Maslow, M., Lemaire, S., Cherfils,
J., Chueca, A., and Lopez-Gorge, J. (1997) FEBS Lett. 401, 143–147
Internal Cysteine of NADP-malate Dehydrogenase 19857
